News

Eli Lilly, compounders partly to blame for Novo CEO’s ouster
CEO resigns as Eli Lilly (LLY) dominates the weight loss drug market and compounders threaten the company's financial outlook ...
BMO's Evan David Seigerman: Novo Nordisk CEO departure reflects disparity with Eli Lilly
Evan David Seigerman, BMO Capital Markets head of healthcare research, joins CNBC's 'Money Movers' to discuss reactions to ...
Novo Nordisk announces CEO transition as share price slips
In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...
Novo Replaces CEO Jorgensen After Lilly Rivalry Hits Shares
Novo Nordisk A/S is replacing Chief Executive Officer Lars Fruergaard Jorgensen as the drugmaker wrestles with increased ...
Novo Nordisk CEO's Surprise Exit After Setbacks in Weight-Loss Market
"The Novo Nordisk Foundation is increasing its influence and has appointed its chairman, Lars Rebien Sørensen, as an observer ...
Fierce Biotech3d
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...
Money Morning2d
Eli Lilly (LLY): Should You Buy or Sell After Drug Price Order?
Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...
Jim Cramer on Eli Lilly and Company (LLY) – “Buy Hand Over Fist – This GLP-1 Giant Just Crushed Novo”
We recently published a list of 13 Stocks on Jim Cramer’s Radar Recently. In this article, we are going to take a look at ...